Orchestra BioMed Holdings (OBIO) Current Deferred Revenue (2021 - 2025)

Orchestra BioMed Holdings (OBIO) has reported Current Deferred Revenue for 5 consecutive years, with $4.6 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Current Deferred Revenue rose 14.34% year-over-year to $4.6 million; the TTM figure through Sep 2025 stood at $4.6 million (up 14.34% YoY), while the FY2024 annual figure was $4.4 million, up 76.85% from the prior year.
• Current Deferred Revenue climbed to $4.6 million in Q3 2025 per OBIO's latest filing, from $4.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $22.4 million in Q4 2021 and bottomed at $2.5 million in Q4 2023.
• Historically, Current Deferred Revenue has averaged $7.7 million across 5 years, with a median of $4.4 million in 2023.
• On a YoY basis, Current Deferred Revenue climbed as much as 76.85% in 2024 and fell as far as 83.42% in 2024.
• Orchestra BioMed Holdings' Current Deferred Revenue stood at $22.4 million in 2021, then sank by 71.27% to $6.4 million in 2022, then slumped by 61.0% to $2.5 million in 2023, then jumped by 76.85% to $4.4 million in 2024, then increased by 4.73% to $4.6 million in 2025.
• Business Quant data shows OBIO's Current Deferred Revenue at $4.6 million in Q3 2025, $4.5 million in Q2 2025, and $3.9 million in Q1 2025.